Scarica l'app Stockscreener
1.085
0.46%
0.005
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday - Defense World
Rani Therapeutics Board Restructures After DeBuono’s Retirement - TipRanks
Ratio Examination: Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Daily Progress: XPLR Infrastructure LP (XIFR) Drop -1.51, Closing at 8.46 - DWinneX
Market Recap: PowerFleet Inc (AIOT)’s Negative Momentum, Closing at 5.12 - DWinneX
Market Highlights: Clear Channel Outdoor Holdings Inc (CCO) Ends on a Low Note at 1.02 - DWinneX
Post-Trade Analysis: Baytex Energy Corp (BTE) Climbs 0.61, Closing at 1.65 - DWinneX
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33 - Defense World
SEC Form DEFA14A filed by Rani Therapeutics Holdings Inc. - Quantisnow
HC Wainwright Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - Defense World
What is Zacks Small Cap’s Forecast for RANI FY2025 Earnings? - Defense World
Rani Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.33 Consensus PT from Analysts - Defense World
Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains - TipRanks
BTIG maintains Buy on Rani Therapeutics stock, $14 target - Investing.com Australia
RANI: 2024 Financial Results - Yahoo Finance
Stifel maintains Buy on Rani Therapeutics, $8 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Rani Therapeutics, $8 target - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript - Insider Monkey
BTIG maintains Buy on Rani Therapeutics stock, $14 target By Investing.com - Investing.com UK
Virtu Financial LLC Invests $62,000 in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) - Defense World
Rani Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 - Investing.com Canada
Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewswire
Breakthrough: Rani's Oral GLP-1 Shows 111% Bioequivalence in Latest Financial Report - Stock Titan
Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
An Overview of Rani Therapeutics Hldgs's Earnings - Benzinga
Stifel maintains Buy on Rani Therapeutics stock, $8 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Rani Therapeutics stock, $8 target - Investing.com India
Rani Therapeutics stock holds buy rating, $14 target from BTIG By Investing.com - Investing.com Canada
Rani Therapeutics reports oral drug matches injectable in obesity study By Investing.com - Investing.com South Africa
Rani Therapeutics reports oral drug matches injectable in obesity study - Investing.com
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102 - MarketScreener
Rani Therapeutics Announces Preclinical Data Demonstrating - GlobeNewswire
Rani Therapeutics (RANI) Announces Preclinical Data Demonstrating Bioequivalence of RT-114 - StreetInsider.com
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - Nasdaq
Rani Therapeutics stock holds buy rating, $14 target from BTIG - Investing.com India
Game-Changing Oral GLP-1 Matches Injectable Performance: New Data Reveals 111% Bioavailability - Stock Titan
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Oral Biologics Pioneer Rani Therapeutics Announces 2024 Year-End Earnings Date - Stock Titan
Rani Therapeutics (RANI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.33 - Defense World
Canaccord Genuity Group Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - The AM Reporter
Rani Therapeutics’ (RANI) Buy Rating Reiterated at Canaccord Genuity Group - Defense World
Canaccord Genuity Group Reiterates Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI: Impressive Bioavailability for RT-116 - Yahoo Finance
Power to the People: How Individual Investors Shape Rani Therapeutics - Smartphone Magazine
0.35%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):